Valuation: Incyte Corporation

Market Cap 2.42TCr 2.11TCr 1.96TCr 1.8TCr 3.4TCr 2,31300Cr 3.45TCr 23TCr 9.07TCr 1,15100Cr 9.1TCr 8.9TCr 3,86100Cr P/E 2026 *
55x
P/E 2027 * 16.5x
Enterprise Value 2TCr 1.74TCr 1.62TCr 1.48TCr 2.8TCr 1,90700Cr 2.85TCr 19TCr 7.48TCr 95TCr 7.5TCr 7.34TCr 3,18400Cr EV / Sales 2026 *
3.36x
EV / Sales 2027 * 2.96x
Free-Float
98.13%
Yield 2026 *
-
Yield 2027 * -
1 day-2.82%
1 week+1.57%
1 month+2.28%
3 months+23.33%
6 months+16.41%
Current year+21.01%
1 week 118.44
Extreme 118.44
132.6
1 month 110.56
Extreme 110.56
132.6
Current year 89.25
Extreme 89.25
132.6
1 year 75.48
Extreme 75.48
132.6
3 years 50.27
Extreme 50.27
132.6
5 years 50.27
Extreme 50.27
132.6
10 years 50.27
Extreme 50.27
153.15
Manager TitleAgeSince
Chief Executive Officer 58 26/06/2025
Director of Finance/CFO 57 04/05/2026
President 62 05/06/2023
Director TitleAgeSince
Chairman 59 26/06/2025
Director/Board Member 72 20/01/2015
Director/Board Member 64 20/01/2015
Date Insider Type Main position Quantity % Market Cap.
23/07/26 Free

Chief Technology Officer

15,425 0.0077%
23/07/26 Free

EVP, Head of Incyte Intl

28,921 0.0145%
16/07/26 Free

EVP & Chief Scientific Officer

46,244 0.0231%
Change 5-day change 1-year change 3-year change Capi.($)
-2.82%+1.57%+58.12%+81.97% 2.42TCr
+3.29%+16.25%+36.46%+4.17% 7.62TCr
+0.43%-8.93%+21.23%+182.50% 4.89TCr
-2.75%+48.50%+48.50%+48.50% 4.78TCr
+1.01%+6.80%-53.08%-53.45% 4.14TCr
-2.40%+0.38%+53.81%-25.27% 3TCr
-5.35%+1.39%+98.59%-50.26% 2.19TCr
-0.81%-3.75%-7.43%+162.20% 1.92TCr
-4.70%-3.41%+66.12%+119.06% 1.71TCr
-2.50%-4.68%+69.07%+150.28% 1.57TCr
Average -1.65%+0.87%+39.14%+61.97% 3.42TCr
Weighted average by Cap. -0.61%+2.63%+32.68%+49.63%

Financials

2026 *2027 *
Net sales 594.27Cr 516.6Cr 480.84Cr 441.47Cr 833.68Cr 57TCr 846.6Cr 5.67TCr 2.22TCr 28TCr 2.23TCr 2.18TCr 95TCr 622.27Cr 540.94Cr 503.5Cr 462.27Cr 872.96Cr 59TCr 886.49Cr 5.93TCr 2.33TCr 30TCr 2.34TCr 2.29TCr 99TCr
Net income 45Cr 39Cr 37Cr 34Cr 63Cr 4.31TCr 64Cr 431.1Cr 169.19Cr 2.15TCr 169.75Cr 166.03Cr 7.2TCr 148.11Cr 128.75Cr 119.84Cr 110.03Cr 207.77Cr 14TCr 210.99Cr 1.41TCr 554.39Cr 7.04TCr 556.23Cr 544.01Cr 24TCr
Net Debt -424.92Cr -369.38Cr -343.82Cr -315.67Cr -596.11Cr -41TCr -605.34Cr -4.05TCr -1.59TCr -20TCr -1.6TCr -1.56TCr -68TCr -581.22Cr -505.25Cr -470.28Cr -431.78Cr -815.37Cr -55TCr -828Cr -5.54TCr -2.18TCr -28TCr -2.18TCr -2.13TCr -93TCr
Logo Incyte Corporation
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (84.7%); - royalties (12.4%); - income from research and cooperation agreements (2.9%).
Employees
2,844
Date Price Change Volume
31/26/31 $119.52 -2.82% 18,30,263
30/26/30 $122.99 -3.23% 26,28,292
29/26/29 $127.10 -2.18% 29,17,698
28/26/28 $129.93 +9.30% 59,21,515
27/26/27 $118.87 +1.02% 27,29,176
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
119.52USD
Average target price
122.96USD
Spread / Average Target
+2.88%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INCY Stock